Notably, POLE mutant, ultra-mutated tumours have greater progression-free survival (PFS) when matched for stage, grade, and morphological subtype, and therefore do not require adjuvant treatment in early stage (I–II) disease [9,10]. Here, POLE is linked to neoplasm.